Prescient Therapeutics to present PTX-100 results at 5th World Congress of Cutaneous Lymphomas
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) will present results of its Phase 1b study of PTX-100 in...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) will present results of its Phase 1b study of PTX-100 in...
In valuing Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) at A11.6 cents per share in its base case and...
Bioshares has a Speculative Buy Class B recommendation for Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) after the company...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF)'s lead compound PTX-100 is potentially a significant future treatment for...
Cancer remains one of the most pressing public health challenges worldwide, affecting millions of lives...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) has had its abstract for PTX-100 published on the American Society...
Results of a Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) Phase 1b study in T cell lymphomas have been accepted...
The prestigious International Society of Cell and Gene Therapy (ISCT) will showcase two abstracts from Prescient...
Prescient Therapeutics Ltd (ASX:PTX) CEO Steven Yatomi-Clarke updates Proactive’s Elisha Newell after the biotech showcased pre-clinical...
The prestigious International Society of Cell and Gene Therapy (ISCT) will showcase two abstracts from Prescient...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.